Loading organizations...
Evanston, Illinois-based Aptinyx is a clinical-stage biopharmaceutical company that develops synthetic small-molecule therapeutics targeting the brain's NMDA receptor to treat central nervous system disorders like Parkinson's disease and post-traumatic stress disorder. The enterprise originated as a spin-out from predecessor company Naurex following that entity's $560 million acquisition by pharmaceutical giant Allergan. Prior to ceasing clinical operations, the firm secured a $65 million venture capital round backed by institutional investors including Adams Street Partners and Frazier Healthcare Partners. The organization subsequently raised $102 million during its 2018 initial public offering and traded on the Nasdaq exchange under the ticker APTX. In 2023, the business announced it would delist and commence a formal liquidation process after its lead drug candidate failed a Phase 2 clinical trial. Aptinyx was founded in 2015 by Norbert Riedel and Joseph Moskal.
Aptinyx has raised $135.0M across 2 funding rounds.
Aptinyx has raised $135.0M in total across 2 funding rounds.
Aptinyx has raised $135.0M across 2 funding rounds. Most recently, it raised $70.0M Series B in December 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2017 | $70M Series B | Bain Capital Life Sciences | 5AM Ventures, Access Biotechnology, Longwood Fund, Adage Capital Management, Adams Street Partners, Agent Capital, Beecken Petty O'keefe & Company, Frazier Healthcare Partners, Goudy Park Capital, HBM Healthcare Investments, Longitude Capital, LVP Life Science Ventures, NAN Fung Life Sciences, NEW Leaf Venture Partners, Northwestern University, Osage University Partners, Partner Fund Management, Pathocapital, Rock Springs Capital | Announced |
| May 1, 2016 | $65M Series A | Liam Ratcliffe | Access Biotechnology, Adams Street Partners, Beecken Petty O'keefe & Company, James Topper, Goudy Park Capital, Patrick Enright, LVP Life Science Ventures, Northwestern University, Osage University Partners, Pathocapital | Announced |
Aptinyx has raised $135.0M in total across 2 funding rounds.
Aptinyx's investors include Bain Capital Life Sciences, 5AM Ventures, Access Biotechnology, Longwood Fund, Adage Capital Management, Adams Street Partners, Agent Capital, Beecken Petty O'Keefe & Company, Frazier Healthcare Partners, Goudy Park Capital, HBM Healthcare Investments, Longitude Capital.
Aptinyx Inc. (NASDAQ: APTX) is a clinical-stage biopharmaceutical company developing novel, proprietary synthetic therapeutics that target synaptic plasticity to treat neurological disorders.[1] It serves patients with conditions like depression, PTSD, and Alzheimer's by addressing impaired neural communication pathways, with a pipeline focused on CNS diseases where current treatments fall short.[1][2] The company has advanced multiple candidates into clinical trials, emphasizing treatments that modulate brain plasticity for better efficacy and safety over traditional options.[1]
Aptinyx emerged as a spin-out from Naurex, launched by a former Naurex team leveraging expertise in synaptic plasticity modulators.[2] The idea stemmed from Naurex's foundational work on enhancing neural cell communication networks, which Aptinyx built upon to create proprietary small-molecule therapeutics.[2] Early traction came from this heritage, positioning Aptinyx to rapidly advance candidates into clinical development post-founding around 2015, amid growing interest in neuroplasticity-based CNS therapies.[1][2]
Aptinyx rides the wave of neuroplasticity innovation in biotech, targeting unmet needs in CNS therapeutics amid a shift from symptom management to disease-modifying treatments.[1][2] Timing aligns with advances in brain science and AI-driven drug discovery, amplifying market forces like aging populations driving Alzheimer's demand and post-pandemic mental health crises boosting PTSD/depression pipelines.[1] It influences the ecosystem by validating plasticity as a therapeutic frontier, potentially inspiring spin-outs and partnerships in precision neurology.
Aptinyx is poised for milestone-driven progress, with potential Phase 2/3 readouts catalyzing partnerships or approvals in high-need CNS areas.[1] Trends like biomarker integration and psychedelic-inspired plasticity research will shape its path, evolving its role from clinical pioneer to potential category leader if data de-risks the platform.[2] Watch for acquisition interest from big pharma eyeing neuroportfolios—this synaptic edge could redefine Aptinyx's trajectory from spin-out to synaptic therapy powerhouse.
